Holen Sie sich die Stockscreener-App
8.89
0.11%
-0.010
Schlusskurs vom Vortag:
$8.90
Offen:
$8.91
24-Stunden-Volumen:
48,433
Relative Volume:
2.56
Marktkapitalisierung:
$32.80M
Einnahmen:
$11.68M
Nettoeinkommen (Verlust:
$-8.85M
KGV:
-3.6888
EPS:
-2.41
Netto-Cashflow:
$-14.61M
1W Leistung:
-1.00%
1M Leistung:
+42.39%
6M Leistung:
+48.17%
1J Leistung:
+367.89%
1-Tages-Spanne:
$8.89
$9.23
1-Wochen-Bereich:
$8.49
$9.23
52-Wochen-Spanne:
$1.78
$10.40
Pulmatrix Inc Stock (PULM) Company Profile
Firmenname
Pulmatrix Inc
Sektor
Branche
Telefon
(888) 355-4440
Adresse
945 CONCORD STREET, FRAMINGHAM, MA
Vergleichen Sie PULM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
8.89 | 32.80M | 11.68M | -8.85M | -14.61M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-02-09 | Eingeleitet | H.C. Wainwright | Buy |
Pulmatrix Inc Aktie (PULM) Neueste Nachrichten
Long Term Trading Analysis for (PULM) - news.stocktradersdaily.com
Financial Comparison: Pulmatrix (NASDAQ:PULM) & Acelyrin (NASDAQ:SLRN) - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com - Defense World
(PULM) Trading Advice - news.stocktradersdaily.com
Pulmatrix set for merger with Cullgen, seeks asset divestment By Investing.com - Investing.com South Africa
Enliven stops work on solid tumor drug; Pulmatrix to divest assets - Endpoints News
Pulmatrix Announces Divestment Plan for Assets - citybiz
Pulmatrix Announces First Quarter 2025 Financial Results and Div - GuruFocus
Pulmatrix, Inc. SEC 10-Q Report - TradingView
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets | PULM Stock News - GuruFocus
Pulmatrix set for merger with Cullgen, seeks asset divestment - Investing.com
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - WV News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders - The Malaysian Reserve
2025-05-13 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders | NDAQ:ICAD | Press Release - Stockhouse
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc.PULM - marketscreener.com
(PULM) Proactive Strategies - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Holdings in Pulmatrix, Inc. (NASDAQ:PULM) - Defense World
Pulmatrix, Inc. (NASDAQ:PULM) Holdings Cut by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
(PULM) Investment Analysis - news.stocktradersdaily.com
Pulmatrix appoints CBIZ as new auditor after Marcum resignation By Investing.com - Investing.com India
Pulmatrix appoints CBIZ as new auditor after Marcum resignation - Investing.com
Pulmatrix Will Discuss Progress At The Aegis Growth Conference On September 21, 2016 - BioSpace
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Pulmatrix : Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline - MarketScreener
Learn to Evaluate (PULM) using the Charts - news.stocktradersdaily.com
Pulmatrix Reports 2024 Financials and Merger Plans - TipRanks
Pulmatrix Inc. (PULM) reports earnings - Quartz
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - Nasdaq
Pulmatrix (NASDAQ:PULM) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Pulmatrix Grows Revenue to $7.8M as Major Strategic Transformation Unfolds - Stock Titan
(PULM) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders - The Malaysian Reserve
2025-02-25 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders | NDAQ:CCNE | Press Release - Stockhouse
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM) - TradingView
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders - Business Wire
PULM stock soars to 52-week high, touches $8.5 amid robust gains - Investing.com India
PULM stock soars to 52-week high, touches $8.5 amid robust gains By Investing.com - Investing.com South Africa
Pulmatrix revises bylaws, changes voting standards - MSN
Pulmatrix revises bylaws, changes voting standards By Investing.com - Investing.com Nigeria
Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke - ACCESS Newswire
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - The Manila Times
SEC Form 425 filed by Pulmatrix Inc. - Quantisnow
Cullgen Begins Phase 1 Dosing of its Potential - GlobeNewswire
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix, Inc. Holds 2024 Annual Meeting of Stockholders – Final Voting Results Released - Defense World
Finanzdaten der Pulmatrix Inc-Aktie (PULM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):